Abstract:Objective:To explore the effect of the acute treatment outcome on the trajectory of residual symptoms for major depressive disorder (MDD).Method:This is a multicenter, prospective, non-intervention study. The MDD patients who self-reported an improvement after received an 8-12 weeks antidepressant treatment were included. Social-demographic and clinical characteristics were collected at the baseline. Brief 16-item Quick Inventory of Depressive Symptomatology Self-Report (QIDS-SR 16), Generalized Anxiety Disorder Scale (GAD-7), Arizona Sexual Experience Scale experience (ASEX), Digital Span Test (DST) and Digit Symbol Substitution Test (DSST) were used to assess the symptoms. Patients were followed up at month 1, 3 and 6. Mix effect model and generalized estimating equation were used to analysis changes over visits of symptoms within or between groups. Result:Totally, 428 eligible patients were included in this study. At baseline, 179 patients achieved remission (41.8%,179/428) and 249 achieved partial remission (58.2%,249/428). There were no significant differences in demographics, clinical characteristics and treatment between the two groups. The proportion of increased appetite, weight gain, suicidal ideation, and restlessness in the remission group did not change significantly over time ( Z=-1.62-1.34, all P>0.003), meanwhile, the proportion of hypersomnia, increased appetite, and weight gain in the partial remission group did not change significantly over the course of the assessments ( Z=-2.43- -1.26, all P>0.003). The proportion of other residual symptoms changed significantly from baseline to 6-month follow-up in both groups ( Z=-10.77- -2.46, all P<0.003), nevertheless, there was no significant difference between the two groups ( Z=0.37-3.26, all P>0.003). The total score of GAD-7 of the two groups were significantly different at each assessment timepoint (χ 2=24.68-113.80, P<0.01), and the improvement of anxiety in the remission group was better than that in the partial remission group ( F=8.39, P<0.01). There were no significant differences in the total ASEX scores between the two groups at each visit ( F=-1.93- -0.68, all P>0.05), and there were no significant difference within the group ( F=0.01-0.17, P>0.05). There was no significant difference in the total scores of DST and DSST between the two groups at baseline ( F=-1.23, -1.14, all P>0.05), and also no significant differences were found during all follow-up visits after control for score at baseline ( F=-1.14- -0.91, all P>0.05). Conclusions:The treatment outcome of the acute phase has an impact on the residual symptoms of MDD. Remission has a positive effect on the improvement of anxiety, but has no significant effect on the improvement of sexual dysfunction and cognitive function.

Antidepressant side effects and their impact on treatment outcome in people with major depressive disorder: an iSPOT-D report

Antidepressant Side Effects in Depression Patients Treated in a Naturalistic Setting: A Study of Bupropion, Moclobemide, Paroxetine, Sertraline, and Venlafaxine

Dimensions of anxiety in Major depressive disorder and their use in predicting antidepressant treatment outcome: an iSPOT-D report

What is the impact of antidepressant side effects on medication adherence among adult patients diagnosed with depressive disorder: A systematic review

Not all types of depressed patients who persist with their antidepressant treatment improve in side effect complaints: A comparison of treatment completers and dropouts in the STAR*D trial

Prediction of antidepressant side effects in the Genetic Link to Anxiety and Depression Study

Do side effects of antidepressants impact efficacy estimates based on the Hamilton Depression Rating Scale? A pooled patient-level analysis

Characterising anxiety in major depressive disorder and its use in predicting antidepressant treatment outcome: An iSPOT-D report

Frequency Of Treatment-Emergent Sexual Dysfunction And Treatment Effectiveness During Ssri Or Duloxetine Therapy: 8-Week Data From A 6-Month Observational Study

Side effects of antidepressants during long-term use in a naturalistic setting

Effects of treatment outcome in acute phase of depression on residual symptoms in a 6-month follow-up: a national, multicenter study

Symptom-level effects of SSRIs in depression studies in a large-scale study programme: efficacy, effects of baseline severity, impact on suicidality, and more

Early symptom non-improvement and aggravation are associated with the treatment response to SSRIs in MDD: a real-world study

Impacts on Quality of Life with Escitalopram Monotherapy and Aripiprazole Augmentation in Patients with Major Depressive Disorder: A CAN-BIND Report

Childhood trauma predicts antidepressant response in adults with major depression: data from the randomized international study to predict optimized treatment for depression

The network analysis of depressive symptoms before and after two weeks of antidepressant treatment

Neurophysiologic Correlates of Side Effects in Normal Subjects Randomized to Venlafaxine or Placebo

Side Effects of Psychotropic Medications Experienced by a Community Sample of People Living With Severe and Persistent Mental Illness

Discontinuation of antidepressant treatment: a retrospective cohort study on more than 20,000 participants

Common selective serotonin reuptake inhibitor side effects in older adults associated with genetic polymorphisms in the serotonin transporter and receptors: data from a randomized controlled trial

Understanding genetic risk factors for common side effects of antidepressant medications